SEARCH

SEARCH BY CITATION

References

  • 1
    Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 186772.
  • 2
    Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 76378.
  • 3
    Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, Gherardi G, Feinleib M. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74: 10238.
  • 4
    Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 17.
  • 5
    Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097105.
  • 6
    Pontiroli AE, Folli F, Paganelli M, Micheletto G, Pizzocri P, Vedani P, Luisi F, Perego L, Morabito A, Bressani Doldi S. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care 2005; 28: 27039.
  • 7
    Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 10427.
  • 8
    Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystik T, Sullivan M, Bouchard C, Carlsson B, Bengsston C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 74152.
  • 9
    Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 22333.
  • 10
    Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T, Pabinger I. Venous thromboembolism – a manifestation of the metabolic syndrome. Haematologica 2007; 92: 37480.
  • 11
    Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, Crowther M, Venco A. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 19148.
  • 12
    Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E, Schernthaner G. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003; 11: 9506.
  • 13
    Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005; 90: 31622.
  • 14
    Sola E, Navarro S, Medina P, Vaya A, Estelles A, Hernandez-Mijares A, Espana F. Activated protein C levels in obesity and weight loss influence. Thromb Res 2009; 123: 697700.
  • 15
    Solá E, Vayá A, España F, Castelló R, Ramón LA, Hernández-Mijares A, Vicente V, Estellés A. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res 2008; 122: 3207.
  • 16
    Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889903.
  • 17
    Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009; 29: 3326.
  • 18
    Mason EE, Ito C. Gastric bypass. Ann Surg 1969; 170: 32939.
  • 19
    Kuzmak LI. Silicone gastric banding: a simple and effective operation for morbid obesity. Contemp Surg 1986; 28: 138.
  • 20
    Kriwanek S, Blauensteiner W, Lebisch E, Beckerhinn P, Roka R. Dietary changes after vertical banded gastroplasty. Obes Surg 2000; 10: 3740.
  • 21
    American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25(Suppl 1): S1147.
  • 22
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 4129.
  • 23
    Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff Am, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898904.
  • 24
    Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007; 92: 43528.
  • 25
    Orbe J, Zudaire M, Serrano R, Coma-Canella I, Martinez de Sizarrondo S, Rodriguez JA, Paramo JA. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99: 3827.
  • 26
    Cimenti C, Mangge H, Haidl H, Zach D, Muntean W. Thrombin generation in severely obese children. J Thromb Haemost 2006; 4: 18346.
  • 27
    Van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 2008; 19: 1839.
  • 28
    Chandler WL, Roshal M. Optimization of plasma fluorogenic thrombin-generation assays. Am J Clin Pathol 2009; 132: 16979.